AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38277197 — intervention group
Group type: COMPARATOR
Intervention: Powered ankle-foot device with current standard of practice (Group B)
Number of subjects: 30
Study 38277204 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Prevention of Posttraumatic Stress Disorder in Military Professionals (PREPARE) program, structured into 8 workshops and 2 debriefing and practice reinforcement workshops.
Number of subjects: 0
Study 38277204 — intervention group
Group type: COMPARATOR
Intervention: No training (nonintervention group).
Number of subjects: 0
Study 38277210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (cTBS)
Number of subjects: 20
Study 38277210 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 38277468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 10584
Study 38277468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10584
Study 38277619 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine, Venetoclax, and Gilteritinib
Number of subjects: 52
Study 38277619 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine plus Venetoclax (standard of care)
Number of subjects: 52
Study 38277865 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIS + GBT
Number of subjects: 48
Study 38277865 — intervention group
Group type: COMPARATOR
Intervention: GBT alone
Number of subjects: 48
Study 38277979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynaecological follow-up
Number of subjects: 192
Study 38277979 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual cervical screening
Number of subjects: 192
Study 38277979 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillomavirus vaccination
Number of subjects: 192
Study 38277979 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use
Number of subjects: 192
Study 38277979 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned pregnancies
Number of subjects: 192
Study 38278170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pozelimab (30 mg/kg loading dose, followed by weekly subcutaneous doses based on body weight)
Number of subjects: 10
Study 38278170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pozelimab
Number of subjects: 10
Study 38278217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime pistachio snack (57 g/d)
Number of subjects: 66
Study 38278217 — intervention group
Group type: COMPARATOR
Intervention: Usual care (education to consume 1-2 carbohydrate exchanges)
Number of subjects: 66
Study 38278357 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Number of subjects: 100
Study 38278357 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 100
Study 38278364 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester (4 g/d)
Number of subjects: 32
Study 38278364 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 38278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-food dietary pattern (36%)
Number of subjects: 3022
Study 38278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Western contemporary dietary pattern (30%)
Number of subjects: 3022
Study 38278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based dietary pattern (20%)
Number of subjects: 3022
Study 38278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-based dietary pattern (14%)
Number of subjects: 3022
Study 38278365 — intervention group
Group type: COMPARATOR
Intervention: Plant-based dietary pattern (38%)
Number of subjects: 3022
Study 38278365 — intervention group
Group type: COMPARATOR
Intervention: Fast-food dietary pattern (29%)
Number of subjects: 3022
Study 38278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-food pattern
Number of subjects: 3022
Study 38278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-based diet
Number of subjects: 3022
Study 38278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-food, Western contemporary, or animal-based diet
Number of subjects: 3022
Study 38278478 — intervention group
Group type: EXPERIMENTAL
Intervention: eSOC+FBT
Number of subjects: 0
Study 38278478 — intervention group
Group type: COMPARATOR
Intervention: eSOC
Number of subjects: 0
Study 38278503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary electrocardiogram (icECG)
Number of subjects: 21
Study 38278503 — intervention group
Group type: COMPARATOR
Intervention: Doppler derived CMD indices (CFR and HMR)
Number of subjects: 21
Study 38278747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever management video training
Number of subjects: 99
Study 38278856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis (LVA)
Number of subjects: 92
Study 38278856 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (CDT)
Number of subjects: 92
Study 38278871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily
Number of subjects: 156
Study 38278871 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 156
Study 38278960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib for 2 years after re-treatment
Number of subjects: 94
Study 38279085 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (30 mg)
Number of subjects: 62
Study 38279085 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (5 mg)
Number of subjects: 62
Study 38279109 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 20
Study 38279124 — intervention group
Group type: EXPERIMENTAL
Intervention: DON 0.1 mg/kg
Number of subjects: 72
Study 38279124 — intervention group
Group type: EXPERIMENTAL
Intervention: DON 1.0 mg/kg
Number of subjects: 72
Study 38279124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 38279131 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Back digital programme
Number of subjects: 30
Study 38279131 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 38279164 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA infection
Number of subjects: 522
Study 38279164 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP assay for MRSA detection
Number of subjects: 522
Study 38279164 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus infection
Number of subjects: 522
Study 38279175 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently unhealthy lifestyle group
Number of subjects: 546
Study 38279175 — intervention group
Group type: COMPARATOR
Intervention: Mixed pattern group
Number of subjects: 546
Study 38279175 — intervention group
Group type: COMPARATOR
Intervention: Consistently healthy group
Number of subjects: 546
Study 38279184 — intervention group
Group type: EXPERIMENTAL
Intervention: far-UVC light devices (222 nm)
Number of subjects: 0
Study 38279184 — intervention group
Group type: COMPARATOR
Intervention: placebo light devices (400-700 nm)
Number of subjects: 0
Study 38279199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program, eight sessions over 4 weeks (two sessions per week)
Number of subjects: 95
Study 38279199 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep relaxation exercises, four times a week for 4 weeks using deep relaxation videos
Number of subjects: 95
Study 38279199 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine prenatal care
Number of subjects: 95
Study 38279199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 95
Study 38279363 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 180 mg subcutaneously once weekly for 5 weeks, then every other week until week 10.
Number of subjects: 39
Study 38279363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 38279364 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 22.5 mg
Number of subjects: 222
Study 38279364 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 45 mg
Number of subjects: 222
Study 38279364 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 90 mg
Number of subjects: 222
Study 38279364 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 135 mg
Number of subjects: 222
Study 38279364 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 180 mg
Number of subjects: 222
Study 38279364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 38279367 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of subcutaneous anifrolumab
Number of subjects: 36
Study 38279367 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of subcutaneous anifrolumab
Number of subjects: 36
Study 38279367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 38279368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous belimumab (10 mg/kg)
Number of subjects: 4018
Study 38279368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4018
Study 38279383 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06826647 400 mg
Number of subjects: 40
Study 38279383 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06826647 100 mg
Number of subjects: 40
Study 38279383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38279390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab once a week
Number of subjects: 215
Study 38279390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab every other week
Number of subjects: 215
Study 38279390 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 26-week prednisone taper
Number of subjects: 215
Study 38279390 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 52-week prednisone taper
Number of subjects: 215
Study 38279390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab alone
Number of subjects: 215
Study 38279390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus glucocorticoids
Number of subjects: 215
Study 38279390 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids alone
Number of subjects: 215
Study 38279402 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 intravenously)
Number of subjects: 56
Study 38279402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 38279402 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 56
Study 38279410 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation device for up to 30 min per day, delivering pulses of 20 kHz
Number of subjects: 30
Study 38279411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg or 10 mg twice daily
Number of subjects: 686
Study 38279575 — intervention group
Group type: EXPERIMENTAL
Intervention: Piclidenoson 3 mg BID
Number of subjects: 529
Study 38279575 — intervention group
Group type: EXPERIMENTAL
Intervention: Piclidenoson 2 mg BID
Number of subjects: 529
Study 38279575 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 529
Study 38279575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 38279662 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 0.75 mg/kg
Number of subjects: 0
Study 38279662 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 1.5 mg/kg
Number of subjects: 0
Study 38279662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38279662 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine (MA) 20 mg
Number of subjects: 0
Study 38279910 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 38279910 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with Timothy grass (SCIT)
Number of subjects: 0
Study 38279910 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT + Dupilumab
Number of subjects: 0
Study 38279910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38280003 — intervention group
Group type: EXPERIMENTAL
Intervention: AK104 (Cadonilimab) therapy
Number of subjects: 21
Study 38280022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) and whole-body vibration (WBV) training
Number of subjects: 60
Study 38280022 — intervention group
Group type: COMPARATOR
Intervention: Normoxia and non-exercise (Control)
Number of subjects: 60
Study 38280052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoemulsion curcumin (NEC, 200 mg/day)
Number of subjects: 42
Study 38280052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 38280066 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 25
Study 38280066 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 25
Study 38280118 — intervention group
Group type: EXPERIMENTAL
Intervention: High tone therapy (HiToP 191 PNP ®)
Number of subjects: 0
Study 38280118 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 0
Study 38280118 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label HiToP PNP ® device (after opt-in)
Number of subjects: 0
Study 38280118 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical application observation group (not specified if treated with HiToP or other)
Number of subjects: 0
Study 38280124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (6-month multifaceted program focused on behavioral changes)
Number of subjects: 80
Study 38280124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 38280124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 80
Study 38280181 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin, etoposide, and atezolizumab
Number of subjects: 403
Study 38280181 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab maintenance therapy
Number of subjects: 403
Study 38280218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096
Study 38280218 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study 38280281 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting bronchodilator (SAB) - 400 µg of salbutamol and 80 µg of ipratropium
Number of subjects: 22
Study 38280281 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting bronchodilator (SAB)
Number of subjects: 22
Study 38280387 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing (scRNA-seq)
Number of subjects: 39
Study 38280387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage NET analyses
Number of subjects: 39
Study 38280392 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 1.0 mg
Number of subjects: 352
Study 38280392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 38280448 — intervention group
Group type: EXPERIMENTAL
Intervention: Iruplinalkib 180 mg once daily (7-day run-in at 60 mg once daily)
Number of subjects: 292
Study 38280448 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 292
Study 38280448 — intervention group
Group type: EXPERIMENTAL
Intervention: Iruplinalkib
Number of subjects: 292
Study 38280448 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 292
Study 38280483 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient integrated palliative and transplant care
Number of subjects: 360
Study 38280483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 38280531 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 28
Study 38280532 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR) with re-excision of incomplete mucosal layer excision (IME)
Number of subjects: 508
Study 38280653 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg every 4 weeks for 24 weeks
Number of subjects: 1282
Study 38280653 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 4 weeks for 24 weeks
Number of subjects: 1282
Study 38280834 — intervention group
Group type: EXPERIMENTAL
Intervention: High socioeconomic status (SES)
Number of subjects: 773
Study 38280834 — intervention group
Group type: EXPERIMENTAL
Intervention: High lifestyle score
Number of subjects: 773
Study 38280834 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle score
Number of subjects: 773
Study 38280834 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint effect of SES and lifestyle factors
Number of subjects: 773
Study 38281006 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (IMV) for ≥ 96 hours
Number of subjects: 7758
Study 38281006 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors identified
Number of subjects: 7758
Study 38281089 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 3082
Study 38281089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-K antagonists (VKAs)
Number of subjects: 3082
Study 38281089 — intervention group
Group type: COMPARATOR
Intervention: All scores tested
Number of subjects: 3082
Study 38281295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib 700 mg once daily
Number of subjects: 460
Study 38281295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib 700 mg once daily in ≥4th-line therapy
Number of subjects: 460
Study 38281309 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg as monotherapy or in combination with a phosphodiesterase 5 inhibitor
Number of subjects: 45
Study 38281309 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 45
Study 38281499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi-TT)
Number of subjects: 28130
Study 38281499 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal capsular group A conjugate (MenA) vaccine
Number of subjects: 28130
Study 38281569 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Sensitivity (CS)
Number of subjects: 1159
Study 38281579 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Number of subjects: 43
Study 38281579 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Number of subjects: 43
Study 38281619 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA (PDTM MTA WHITE)+SSC
Number of subjects: 64
Study 38281619 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA+GI (bulk fill glass ionomer with glass hybrid technology GC EQUIA Forte® HT)
Number of subjects: 64
Study 38281619 — intervention group
Group type: EXPERIMENTAL
Intervention: BC RRM-F+GI
Number of subjects: 64
Study 38281619 — intervention group
Group type: EXPERIMENTAL
Intervention: BC RRM-F+SCC
Number of subjects: 64
Study 38281619 — intervention group
Group type: COMPARATOR
Intervention: GI
Number of subjects: 64
Study 38281619 — intervention group
Group type: COMPARATOR
Intervention: SCC
Number of subjects: 64
Study 38281914 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor-based immunotherapy in MSI-H patients
Number of subjects: 887
Study 38281914 — intervention group
Group type: COMPARATOR
Intervention: MSI-H status
Number of subjects: 887
Study 38281994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 694
Study 38282003 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 plus chemotherapy (with or without bevacizumab)
Number of subjects: 91
Study 38282192 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (PTAH)
Number of subjects: 269
Study 38282192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 38282258 — intervention group
Group type: EXPERIMENTAL
Intervention: reduction counseling + nicotine mini-lozenges + encouragement to quit starting 1 month post-randomization (preparation)
Number of subjects: 1154
Study 38282258 — intervention group
Group type: EXPERIMENTAL
Intervention: recycling (immediate encouragement to quit)
Number of subjects: 1154
Study 38282258 — intervention group
Group type: COMPARATOR
Intervention: quitline referral (control)
Number of subjects: 1154
Study 38282258 — intervention group
Group type: EXPERIMENTAL
Intervention: skill training (on vs off)
Number of subjects: 1154
Study 38282258 — intervention group
Group type: EXPERIMENTAL
Intervention: supportive counseling (on vs off)
Number of subjects: 1154
Study 38282258 — intervention group
Group type: EXPERIMENTAL
Intervention: preparation (reduction counseling)
Number of subjects: 1154
Study 38282258 — intervention group
Group type: EXPERIMENTAL
Intervention: recycling
Number of subjects: 1154
Study 38282387 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss ≥2 kg
Number of subjects: 21028
Study 38282387 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain ≥5 kg
Number of subjects: 21028
Study 38282387 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight to normal weight
Number of subjects: 21028
Study 38282387 — intervention group
Group type: EXPERIMENTAL
Intervention: Becoming underweight
Number of subjects: 21028
Study 38282387 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable overweight
Number of subjects: 21028
Study 38282503 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL 0.25% bupivacaine
Number of subjects: 80
Study 38282503 — intervention group
Group type: COMPARATOR
Intervention: 20 mL 0.25% bupivacaine
Number of subjects: 80
Study 38282695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive meditation training (10-day Vipassana meditation retreat, 100 hr of sitting meditation)
Number of subjects: 58
Study 38283151 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective screening using LC-MS/MS method
Number of subjects: 750
Study 38283244 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation with reduced-intensity conditioning and protracted immune suppression
Number of subjects: 2